Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ZAHRA T ALIMOHAMMAD

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1114248978
CMS profile
1366794
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$74.18

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $74.18 2

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Tandem Diabetes Care, Inc. $57.83 1
Allergan Inc. $16.35 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ZAHRA T ALIMOHAMMAD

NPI 1114248978 · CMS profile ID 1366794

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1114248978?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ZAHRA T ALIMOHAMMAD, NPI 1114248978, CMS profile ID 1366794. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1114248978?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ZAHRA T ALIMOHAMMAD, NPI 1114248978, CMS profile ID 1366794. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1114248978?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ZAHRA T ALIMOHAMMAD, NPI 1114248978, CMS profile ID 1366794, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1114248978?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $74.18 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Allergan Inc. $16.3510/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670018871 CMS
Tandem Diabetes Care, Inc. $57.8308/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707450023 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $74.18 2
PY2024 $24.34 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2020 Principal investigator $4,168.00 3
PY2019 Principal investigator $241,197.17 68

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

68 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $2,528.15 12/30/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654256809
Principal investigator 1 Janssen Research & Development, LLC $4,147.00 12/23/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654256807
Principal investigator 1 Neurocrine Biosciences, Inc. $8,877.50 12/05/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686568231
Principal investigator 1 Janssen Research & Development, LLC $822.00 11/25/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654256811
Principal investigator 1 Neurocrine Biosciences, Inc. $203.00 11/14/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686567947
Principal investigator 1 Janssen Research & Development, LLC $1,493.00 10/28/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654256805
Principal investigator 1 Allergan Inc. $225.00 10/22/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670088693
Principal investigator 1 Allergan Inc. $225.00 10/22/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
AN OPEN LABEL, LONG TERM SAFETY STUDY OF RAPASTINEL AS AN ADJUNCTIVE THERAPY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER MDD. No dispute reported 06/30/2026 670088869
Principal investigator 1 Janssen Research & Development, LLC $2,268.00 10/11/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654256803
Principal investigator 1 Neurocrine Biosciences, Inc. $0.77 10/03/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686567651
Principal investigator 1 Janssen Research & Development, LLC $1,895.00 09/30/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654256799
Principal investigator 1 Janssen Research & Development, LLC $3,105.00 09/27/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654256801
Principal investigator 1 Janssen Research & Development, LLC $2,777.00 08/26/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654256795
Principal investigator 1 Allergan Inc. $24,845.35 08/22/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670067759
Principal investigator 1 Neurocrine Biosciences, Inc. $8.87 08/22/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686567189
Principal investigator 1 Janssen Research & Development, LLC $907.73 08/01/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654256793
Principal investigator 1 Janssen Research & Development, LLC $1,899.52 08/01/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654256797
Principal investigator 1 Janssen Research & Development, LLC $3,776.00 07/26/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654256791
Principal investigator 1 Neurocrine Biosciences, Inc. $266.00 07/25/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
ROLLOVER STUDY FOR CONTINUING NBI-98854 ADMINISTRATION IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686567013
Principal investigator 1 Allergan Inc. $34,735.80 07/23/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670059721
Principal investigator 1 Neurocrine Biosciences, Inc. $0.77 07/11/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686566877
Principal investigator 1 Janssen Research & Development, LLC $2,730.00 06/28/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654256789
Principal investigator 1 Neurocrine Biosciences, Inc. $7,034.65 06/27/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686566791
Principal investigator 1 Allergan Inc. $36,493.30 06/25/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670053089
Principal investigator 1 Neurocrine Biosciences, Inc. $311.00 06/20/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686566633
Principal investigator 1 Janssen Research & Development, LLC $822.00 05/27/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654256785
Principal investigator 1 Janssen Research & Development, LLC $540.39 05/06/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654256787
Principal investigator 1 Janssen Research & Development, LLC $3,776.00 04/26/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654256783
Principal investigator 1 Allergan Inc. $15,033.75 04/23/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670039555
Principal investigator 1 Neurocrine Biosciences, Inc. $13,013.76 04/11/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
SAFETY, TOLERABILITY, AND EFFICACY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686565699
Principal investigator 1 Neurocrine Biosciences, Inc. $4,449.12 04/04/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686565373
Principal investigator 1 Neurocrine Biosciences, Inc. $5.65 04/04/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686565495
Principal investigator 1 Neurocrine Biosciences, Inc. $5.65 04/04/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686565571
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,263.00 04/03/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIAL LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685007885
Principal investigator 1 Janssen Research & Development, LLC $2,790.00 03/25/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654256781
Principal investigator 1 Allergan Inc. $7,795.70 03/19/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
LVM-MD-14 PREAPMRPHASE 3DOUBLE-BLIND No dispute reported 06/30/2026 670031441
Principal investigator 1 Neurocrine Biosciences, Inc. $5,318.55 03/14/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686564957
Principal investigator 1 Neurocrine Biosciences, Inc. $203.00 02/28/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
SAFETY, TOLERABILITY, AND EFFICACY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686564807
Principal investigator 1 Neurocrine Biosciences, Inc. $464.00 02/28/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686564867
Principal investigator 1 F. Hoffmann-La Roche AG $2,711.47 02/26/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
V1A 2 IN PEDIATRIC AUTISM No dispute reported 06/30/2026 857157511
Principal investigator 1 Janssen Research & Development, LLC $3,105.00 02/25/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654256779
Principal investigator 1 Janssen Research & Development, LLC $4,311.00 02/15/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654256771
Principal investigator 1 Janssen Research & Development, LLC $3,570.00 02/15/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654256775
Principal investigator 1 Janssen Research & Development, LLC $2,660.00 02/15/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654256777
Principal investigator 1 Neurocrine Biosciences, Inc. $1,910.68 02/07/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686564375
Principal investigator 1 Neurocrine Biosciences, Inc. $10,418.40 02/07/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686564377
Principal investigator 1 Neurocrine Biosciences, Inc. $5.18 01/31/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686564097
Principal investigator 1 Neurocrine Biosciences, Inc. $4.51 01/31/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
ROLLOVER STUDY FOR CONTINUING NBI-98854 ADMINISTRATION IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686564107
Principal investigator 1 Neurocrine Biosciences, Inc. $27.56 01/31/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686564113
Principal investigator 1 Neurocrine Biosciences, Inc. $5.18 01/31/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
SAFETY, TOLERABILITY, AND EFFICACY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686564129
Principal investigator 1 Janssen Research & Development, LLC $1,493.00 01/28/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654256773
Principal investigator 1 Neurocrine Biosciences, Inc. $2,091.56 01/10/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563519
Principal investigator 1 Neurocrine Biosciences, Inc. $7,661.92 01/10/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS LLC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563521
Principal investigator 1 Neurocrine Biosciences, Inc. $5.65 01/10/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563821
Principal investigator 1 Neurocrine Biosciences, Inc. $338.00 01/10/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563835
Principal investigator 1 Neurocrine Biosciences, Inc. $86.00 01/03/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686562675
Principal investigator 1 Neurocrine Biosciences, Inc. $46.00 01/03/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686562805
Principal investigator 1 Neurocrine Biosciences, Inc. $5.65 01/03/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563251
Principal investigator 1 Neurocrine Biosciences, Inc. $64.00 01/03/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563263
Principal investigator 1 Neurocrine Biosciences, Inc. $86.00 01/03/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563275
Principal investigator 1 Neurocrine Biosciences, Inc. $64.00 01/03/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
ROLLOVER STUDY FOR CONTINUING NBI-98854 ADMINISTRATION IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563281
Principal investigator 1 Neurocrine Biosciences, Inc. $46.00 01/03/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
SAFETY, TOLERABILITY, AND EFFICACY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563285
Principal investigator 1 Neurocrine Biosciences, Inc. $23.50 01/03/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563295
Principal investigator 1 Neurocrine Biosciences, Inc. $2.93 01/03/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563305
Principal investigator 1 Neurocrine Biosciences, Inc. $128.00 01/03/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563315
Principal investigator 1 Neurocrine Biosciences, Inc. $92.00 01/03/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563327
Principal investigator 1 Neurocrine Biosciences, Inc. $86.00 01/03/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563341
Principal investigator 1 Neurocrine Biosciences, Inc. $92.00 01/03/2019 Non-covered Recipient Entity
RELARO MEDICAL TRIALS
SAFETY, TOLERABILITY, AND EFFICACY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 686563343